PleskMedia Desk The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an “eye stroke,” is a rare condition…
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an “eye stroke,” is a rare condition…
Source: thehill.com
Pleskmedia Media Is a Global News Platform Covering the Latest Developments and Breaking Stories from Around The World, Including World News, Business, Finance, Technology, Health, Politics, Science, Entertainment, Sports, and More.
